Informações: Esta não é a versão mais recente do modelo de dados. Uma visão geral da versão pode ser encontrada à esquerda em Versões. Para a versão mais recente, clique aqui.
Informações:
Falhas:
ID
18321
Descrição
A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD1839; ODM derived from: https://clinicaltrials.gov/show/NCT00212108
Link
https://clinicaltrials.gov/show/NCT00212108
Palavras-chave
Versões (2)
- 31/10/2016 31/10/2016 -
- 31/10/2016 31/10/2016 -
Transferido a
31 de outubro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Nasopharyngeal Carcinoma NCT00212108
Eligibility Nasopharyngeal Carcinoma NCT00212108
- StudyEvent: Eligibility
Similar models
Eligibility Nasopharyngeal Carcinoma NCT00212108
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Nasopharyngeal carcinoma
Item
1. histologically proven npc.
boolean
C2931822 (UMLS CUI [1])
Nasopharyngeal carcinoma | TNM clinical staging
Item
2. any clinical stage npc as defined by the ajcc/uicc system.
boolean
C2931822 (UMLS CUI [1])
C3258246 (UMLS CUI [2])
C3258246 (UMLS CUI [2])
Therapeutic radiology procedure | Chemoradiotherapy | Immunotherapy | Investigational New Drugs
Item
3. no prior radiotherapy, chemoradiotherapy, immunotherapy or investigational agents.
boolean
C1522449 (UMLS CUI [1])
C0436307 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
C0436307 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0013230 (UMLS CUI [4])
Anti-Inflammatory Agents, Non-Steroidal | Adrenal Cortex Hormones
Item
4. no prior nsaids or corticosteroids for at least 4 weeks.
boolean
C0003211 (UMLS CUI [1])
C0001617 (UMLS CUI [2])
C0001617 (UMLS CUI [2])
ECOG performance status
Item
5. ecog performance status ≤ 2.
boolean
C1520224 (UMLS CUI [1])
organ function
Item
6. adequate end organ function
boolean
C0678852 (UMLS CUI [1])
Life Expectancy
Item
7. life expectancy > 3 months.
boolean
C0023671 (UMLS CUI [1])
Informed Consent
Item
8. signed informed consent -
boolean
C0021430 (UMLS CUI [1])
ID.9
Item
1. inability to take celecoxib and gefitinib for the specified period of time (14 days) prior to definitive therapy.
boolean
ID.10
Item
2. tumor not visible on fibre nasopharyngoscopy for biopsy.
boolean
Peptic Ulcer
Item
3. known peptic ulcer disease.
boolean
C0030920 (UMLS CUI [1])
ID.12
Item
4. evidence of clinically active interstitial lung disease.
boolean
ID.13
Item
5. previous or concomitant malignancies with the exception of adequately treated carcinoma-in-situ of the cervix and basal or squamous cell carcinoma of the skin.
boolean
ID.14
Item
6. women who are pregnant or lactating. females with child-bearing potential must have a negative serum pregnancy test within 7 days prior to study enrolment.
boolean
Childbearing Potential Contraceptive methods Lacking
Item
7. women of childbearing potential who are not practising adequate contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
C0700589 (UMLS CUI [1,2])
C0332268 (UMLS CUI [1,3])
ID.16
Item
8. concurrent medical problems that would significantly limit compliance with the study.
boolean
ID.17
Item
9. presence of any underlying medical conditions (eg. unstable or uncompensated respiratory, cardiac, renal or hepatic disease) that in the opinion of the investigator would make the patient unsuitable for study participation.
boolean
ID.18
Item
10. known hypersensitivity to celecoxib and gefitinib or any of the excipients of the products, known sulphonamide sensitivity and allergic reaction following the ingestion of nsaids.
boolean
ID.19
Item
11. known hiv, hbv or hcv infection. -
boolean